Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in Wegener's Granulomatosis
NCT00005007Phase 3Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jun 2000
- Primary completion
- Mar 2003
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in granulomatosis with polyangiitis (GPA) comparing Etanercept with Placebo (2 arms). Primary endpoint: Number of patients who achieve sustained remissions. Started Jun 2000; status: completed.
02
Drugs
etanercept
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT00005007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005007.